MINSK, 19 June (BelTA) – The R&D and manufacturing complex Nativita will be opened in Beshenkovichi, Vitebsk Oblast on 13 July, BelTA learned from Viktor Shein, Deputy Director of the Pharmaceutical Industry Department, Head of the Economy and Marketing Office of the Belarusian Healthcare Ministry, on 19 June.
According to the source, the new pharmaceutical enterprise, which will be opened on 13 July, will focus on making cancer medications.
Nativita is a joint venture established with assistance of Lithuanian, Slovak, Indian, and Belarusian capital. It is a breakthrough project, which demonstrates the appeal of Belarus in the eyes of foreign investors. It also demonstrates the desire of the investors to locally make the medications, which are not manufactured by Belarusian pharmaceutical companies.
In particular, the enterprise will make the first generic medications designed to treat oncological diseases and other ones. These medications will be able to target specific genetic breakages. At present these medications are mainly imported at the expense of millions of U.S dollars in state budget funds. Once the new enterprise is operational, cheaper medications will become available to Belarusians.More about Economy